Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | -49.79% | -32.01% | -37.00% | -41.83% | -30.68% |
| Gross Profit | -165.69% | -398.63% | -479.32% | -589.43% | 152.99% |
| SG&A Expenses | -58.61% | -18.71% | 48.21% | -25.81% | 38.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 63.31% | 72.86% | 51.76% | -173.20% | -160.82% |
| Total Operating Expenses | -53.68% | -32.59% | -3.98% | -30.02% | -0.14% |
| Operating Income | 40.75% | 12.00% | -27.86% | 13.38% | 21.93% |
| Income Before Tax | 39.65% | 19.66% | -8.83% | -29.47% | -6.46% |
| Income Tax Expenses | -255.32% | -482.76% | -297.73% | 86.74% | 96.80% |
| Earnings from Continuing Operations | 39.85% | 19.88% | -8.62% | -31.21% | -8.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -48.72% | -73.86% | -72.48% | 23.64% | 0.00% |
| Net Income | 39.84% | 19.81% | -8.77% | -31.22% | -8.84% |
| EBIT | 40.75% | 12.00% | -27.86% | 13.38% | 21.93% |
| EBITDA | 38.09% | 9.92% | -28.99% | 14.88% | 24.50% |
| EPS Basic | 40.76% | 21.37% | -5.86% | -26.50% | -5.00% |
| Normalized Basic EPS | 40.77% | 12.45% | -27.60% | 15.67% | 25.46% |
| EPS Diluted | 40.55% | 21.27% | -5.79% | -26.19% | -4.91% |
| Normalized Diluted EPS | 40.77% | 12.45% | -27.60% | 15.67% | 25.46% |
| Average Basic Shares Outstanding | 1.88% | 2.40% | 3.00% | 3.60% | 3.39% |
| Average Diluted Shares Outstanding | 1.88% | 2.40% | 3.00% | 3.60% | 3.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |